SUBSCRIBE
SUBSCRIBE

POINT Biopharma

NEWS
POINT Biopharma was acquired by Eli Lilly and Company in December 2023.
Pictured: Eli Lilly's biotechnology center in San
Drug Development
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
While the candidate was effective in Phase III results, Point’s stock price fell following the announcement.
December 18, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: American cash shaped into a funnel/iStoc
Deals
Early October Sees Torrid Pace of Biotech M&A—Will It Continue?
The first two weeks of October saw BMS’s $4.8 billion buyout of Mirati, Lilly’s $1.4 billion purchase of Point, Kyowa Kirin’s $387 million acquisition of Orchard and AbbVie’s $110 million Mitokinin deal.
October 13, 2023
 · 
2 min read
 · 
Greg Slabodkin
IN THE PRESS
Deals
Lilly Completes Acquisition of POINT Biopharma
December 27, 2023
 · 
4 min read
Drug Development
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023
 · 
10 min read
Deals
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
December 4, 2023
 · 
6 min read
Deals
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
November 14, 2023
 · 
6 min read
Business
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 13, 2023
 · 
12 min read
Deals
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
November 8, 2023
 · 
7 min read
Deals
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
October 3, 2023
 · 
10 min read